# Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)

> **NCT01765361** · — · COMPLETED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 16 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01765361
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2015-01
- **Final completion:** 2017-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01765361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01765361, "Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01765361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*